Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors.
about
Human von Willebrand factor/factor VIII concentrates in the management of pediatric patients with von Willebrand disease/hemophilia AEmerging and future therapies for hemophiliaGlobal Post-Authorization Safety Surveillance Study: real-world data on prophylaxis and on-demand treatment using FEIBA (an activated prothrombin complex concentrate).Treatment and Prevention of Bleeds in Haemophilia Patients with Inhibitors to Factor VIII/IXCurrent and evolving features in the clinical management of haemophiliaPrinciples of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in ItalyHematopoietic stem-cell gene therapy of hemophilia A incorporating a porcine factor VIII transgene and nonmyeloablative conditioning regimens.New treatments in hemophilia: insights for the clinician.Haemophilia therapies.International workshop on immune tolerance induction: consensus recommendations.Syngeneic transplantation of hematopoietic stem cells that are genetically modified to express factor VIII in platelets restores hemostasis to hemophilia A mice with preexisting FVIII immunityThe use of factor VIII/von Willebrand factor concentrate for immune tolerance induction in haemophilia A patients with high-titre inhibitors: association of clinical outcome with inhibitor epitope profile.Key issues in inhibitor management in patients with haemophilia.Management of acute haemarthrosis in haemophilia A without inhibitors: literature review, European survey and recommendations.Immune tolerance induction in haemophilia: evidence and the way forward.Immune tolerance induction for patients with severe hemophilia A: a critical literature review.Immune tolerance induction in patients with severe hemophilia with inhibitors: expert panel views and recommendations for clinical practice.Management of bleeding disorders in adults.The reversal of inhibitors in congenital hemophilia.A review of immune tolerance induction with Haemate P in haemophilia A.Effect of von Willebrand factor on inhibitor eradication in patients with severe haemophilia A: a systematic review.ITI choice for the optimal management of inhibitor patients - from a clinical and pharmacoeconomic perspective.Current management of the hemophilic child: a demanding interlocutor. Quality of life and adequate cost-efficacy analysis.Non-genetic risk factors in haemophilia A inhibitor management - the danger theory and the use of animal models.Survey of the anti-factor IX immunoglobulin profiles in patients with hemophilia B using a fluorescence-based immunoassay.Immune tolerance induction in patients with haemophilia a and inhibitors: effectiveness and cost analysis in an European Cohort (The ITER Study).Prompt immune tolerance induction at inhibitor diagnosis regardless of titre may increase overall success in haemophilia A complicated by inhibitors: experience of two U.S. centres.Perceived challenges and attitudes to regimen and product selection from Italian haemophilia treaters: the 2013 AICE survey.Immune tolerance induction in 31 children with haemophilia A: is ITI less successful in African Americans?The International Immune Tolerance Induction Study and its follow-up study on Japanese hemophilia A patients with inhibitors.Immune response against serial infusion of factor VIII antigen through an implantable venous-access device system in haemophilia A mice.Healthcare resource utilization among haemophilia A patients in the United States.European principles of haemophilia care.First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study.Antibody response to recombinant human coagulation factor VIII in a new rat model of severe hemophilia A.Management of patients with long-term inhibitors: is immune tolerance an underestimated life-long solution?Immune tolerance induction in haemophilia A patients with inhibitors by treatment with recombinant factor VIII: a retrospective non-interventional study.High-dose intravenous interferon beta in patients with neutralizing antibodies (HINABS): a pilot study.
P2860
Q26738507-B3A34571-352B-4963-8FE3-0EEF78406785Q26781143-2E057967-3AC1-45C2-BEFB-37512795F2F6Q31041664-13E76508-9D2F-466F-9717-81E938E8DF6BQ33608230-CF4CC0F1-CC4C-4433-AB03-AC56B3E652FEQ33708976-97730697-35A9-4E90-A107-5AF1C72EB6B1Q34416394-8770A3C1-5BAC-4FA5-A0CA-BB795E4C4D07Q36059597-523BFE33-52AC-4448-AADF-8E68878035DEQ36612681-84FB659B-E4D3-4B7F-93D5-A9BACBA57B6DQ36810282-E0A02FA6-9210-451C-AAF5-076309668D76Q36861097-9FF49335-D038-4264-A6EE-B3B83B4C2F5DQ36915859-B59E016A-A143-4814-A63F-FBE09F56AB3DQ37032857-F36127E4-C8B7-4CBA-81D9-1F3938834048Q37602415-875AD2FE-1120-44B9-948F-BB02682E79EAQ37842684-F63722A5-7FEE-41A4-B571-14FAA8CFBBB0Q37903944-4DB8B362-B56E-4AC1-853D-D733202486A8Q37912059-1C616F14-6ECD-4FA5-94DA-166CFE04DFE6Q37977140-163D7AFE-5D46-4D84-B496-C201A05F302CQ38005180-D5C95E66-3027-4E7E-B519-73B105758DA9Q38077139-478D1A85-70C1-4425-8051-F8C68545BC4CQ38156000-3FB8FE96-4EFD-4BD5-8401-30F510644E93Q38212494-FFDC42A4-A71D-4CE0-AD04-F6C482C763A1Q38224296-E1F7F642-D161-41C3-BE65-0B5FE2723970Q38227605-BC972FA8-FE69-456D-AA22-FC80A0B4BCEBQ38937408-F78058AE-4215-4AD1-A3F4-E543239665CFQ39512337-FC489106-5496-4F75-8BA5-68D88C283893Q40638146-6144D589-8261-44AB-AC38-F8B53639CC78Q41592459-DE12D579-D6C6-4305-8835-9F377B6EB5B5Q42236600-8D07E43B-A3D7-4ED8-8CD0-54A567AD4A0AQ45865338-CE9DDE3B-E173-4423-8AAB-90705C99CCB9Q45873133-D16358BE-597A-4CA0-8905-BB407C5FD9C8Q45874582-05C7D8E2-90B4-4BF3-8A08-01A95B6D9D49Q45874612-FCB2B17C-79CD-4F91-8864-3BBA7CD2DDFEQ45874963-ABA015C7-2980-4945-9C74-83C88A5C0629Q45877949-53917C22-016F-496F-9B3E-05D4681829FCQ45882401-F8040954-F313-4F4B-9461-826805CA650CQ45884062-2AEEF174-CFF8-49E0-8CCF-72EF4CD4D9D8Q45885860-5BAA8DEA-456B-432F-95FF-F73E5727C8A9Q45998750-A4C45C19-8A80-4451-ADB7-E6D8F8414ED2
P2860
Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Current European practice in i ...... th haemophilia and inhibitors.
@ast
Current European practice in i ...... th haemophilia and inhibitors.
@en
type
label
Current European practice in i ...... th haemophilia and inhibitors.
@ast
Current European practice in i ...... th haemophilia and inhibitors.
@en
prefLabel
Current European practice in i ...... th haemophilia and inhibitors.
@ast
Current European practice in i ...... th haemophilia and inhibitors.
@en
P2093
P2860
P1433
P1476
Current European practice in i ...... ith haemophilia and inhibitors
@en
P2093
A Gringeri
H M van den Berg
J Astermark
M Schiavoni
M von Depka
P2860
P304
P356
10.1111/J.1365-2516.2006.01296.X
P577
2006-07-01T00:00:00Z